Religox

Religox tablets should be taken orally, with or without food. For faster onset of action, it may be taken without food. Do not chew or crush the tablet; swallow it whole with water.

Religoxib selectively inhibits cyclooxygenase-2 (COX-2), an enzyme responsible for the synthesis of prostaglandins that mediate pain, inflammation, and fever. By inhibiting COX-2, religoxib reduces the production of these inflammatory mediators, thereby providing analgesic, anti-inflammatory, and antipyretic effects, while sparing COX-1, which is involved in gastric protection and platelet function.

• Hypersensitivity to religoxib or any component of the tablet
• Active peptic ulceration or gastrointestinal bleeding
• Severe hepatic dysfunction
• Severe uncontrolled hypertension
• Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
• Congestive heart failure (NYHA Class II-IV)
• Third trimester of pregnancy

Store in a cool and dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.

In case of overdose, symptomatic and supportive measures should be initiated. There is no specific antidote. Dialysis is unlikely to be effective due to high protein binding. Closely monitor vital signs and manage symptoms such as gastrointestinal upset, renal dysfunction, or cardiovascular events.

Pregnancy Category C (D in third trimester). Avoid use in the third trimester due to potential premature closure of the ductus arteriosus. Use only if potential benefit justifies potential risk to the fetus during the first and second trimesters. It is not known whether religoxib is excreted in human milk; caution should be exercised when administered to a nursing mother.

• Hypersensitivity to religoxib or any component of the tablet
• Active peptic ulceration or gastrointestinal bleeding
• Severe hepatic dysfunction
• Severe uncontrolled hypertension
• Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
• Congestive heart failure (NYHA Class II-IV)
• Third trimester of pregnancy

Store in a cool and dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.

In case of overdose, symptomatic and supportive measures should be initiated. There is no specific antidote. Dialysis is unlikely to be effective due to high protein binding. Closely monitor vital signs and manage symptoms such as gastrointestinal upset, renal dysfunction, or cardiovascular events.

Pregnancy Category C (D in third trimester). Avoid use in the third trimester due to potential premature closure of the ductus arteriosus. Use only if potential benefit justifies potential risk to the fetus during the first and second trimesters. It is not known whether religoxib is excreted in human milk; caution should be exercised when administered to a nursing mother.